The CMS appeals committee ruled Medihelp can deny Elaprase therapy for a young Hunter syndrome patient, citing solvency over PMB obligations.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
Tagged , , , , ,